GERMANTOWN, MARYLAND / ACCESS Newswire / March 4, 2025 / uBriGene Biosciences (uBriGene), a leading cell and gene therapy CDMO, is pleased to announce the submission of its Drug Master File (DMF) for ...

Faster Clinical Translation and Commercialization of Therapies Derived From iPSC Technology GERMANTOWN, MARYLAND / ACCESS Newswire / March 4, 2025 / uBriGene Biosciences (uBriGene), a leading cell and ...

GERMANTOWN, MD / ACCESS Newswire / September 17, 2025 / uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, today announced the launch of its 2nd-Generation iPSC ...

RNA-LNP Based, Non-Viral Delivery - RNA-LNP delivery avoids genome integration risks, leaving no genetic footprint. Optimized for PBMCs - The only non-viral kit proven effective for PBMC reprogramming ...

ROCKVILLE, MD / ACCESS Newswire / June 16, 2025 / uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to announce the launch of its fully characterized, ready-to-use induced ...

New York, May 02, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And ...

SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S.

The 5th iPSC Drug Development Summit serves as a pivotal platform for uniting iPSC-based drug developers across the value chain, from research and development through to CMC, to accelerate the ...

Dublin, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2034" report has been added to ResearchAndMarkets.com's offering. This ...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its ...